Table 3.
Sites of disease progression triggering discontinuation of pazopanib
Primary sites of progression | Clinical deterioration | |||
---|---|---|---|---|
Target only | Target and non-target | New and non-target | ||
Partial response | 3 | 1 | 8 | 0 |
Stable disease | 3 | 0 | 3 | 1 |
Progression | 1 | 0 | 6 | 1 |
Total | 7 | 1 | 17 | 2 |